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Pulmonary embolism remains a common and potentially life-threatening disease. For patients with intermediate- and high-risk pulmonary
embolism, catheter-based revascularization therapy has emerged as potential alternative to systemic thrombolysis or surgical embolectomy.
Ultrasound-assisted catheter-directed thrombolysis is a contemporary catheter-based technique and is the focus of the present review. Ultra-
sound-assisted catheter-directed thrombolysis ismore effective in reversing right ventricular dysfunction and dilatation in comparisonwith antic-
oagulationalone inpatientsat intermediate risk.However, adirect comparisonofultrasound-assisted thrombolysiswith systemic thrombolysisor
surgical thrombectomy is not available. Ultrasound-assisted thrombolysis with initial intrapulmonary thrombolytic bolus may also be effective in
high-risk patients, but evidence from randomized trials is not available. This review summarizes current data on ultrasound-assisted thrombolysis
for acute pulmonary embolism.
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Introduction
Pulmonary embolism (PE) spans a broad spectrum of clinical out-
comes and remains a life-threatening disease.1,2 In the International
Cooperative Pulmonary Embolism Registry (ICOPER), the mortality
rate at 3 months was 17%, with nearly half of deaths directly attribut-
able to PE.3 Early clinical outcomes mainly depend on initial haemo-
dynamic status and the extent of right ventricular dysfunction.
Various prognostic models have been developed to classify patients
into risk groups. The simplified Pulmonary Embolism Severity Index
(sPESI) stratifies patients by clinical parameters only,4while the Euro-
pean Society of Cardiology (ESC) model includes imaging and bio-
marker test results of right ventricular dysfunction and myocardial
injury.2,5 According to the ESC model, high-risk PE is defined as PE
with sustained systemic arterial hypotension, cardiogenic shock, or
the need for cardiopulmonary resuscitation, and is associated with
an in-hospital mortality rate .15%.6 Haemodynamically stable
patientswithout right ventriculardysfunctionandnormal cardiacbio-
markers are classified as low-risk patients with mortality rates ,3%.
Haemodynamically stable patients with evidence of right ventricular
dysfunction or positive biomarkers are classified as intermediate-risk
patients with mortality rates of 3–15%.2 The initial stratification of
PE patients into different risk groups has an important impact on
the various treatment options, in particular for the use of revascular-
ization therapy such as systemic thrombolysis, catheter-based treat-
ment, or surgical embolectomy.2,7,8
Revascularization therapy
Several randomized controlled trials have consistently shown that
systemic thrombolysis rapidly improves right ventricular function
and haemodynamic parameters in patients with acute PE.9,10
However, theeffect of systemic thrombolysison recurrent thrombo-
embolic events and mortality remains controversial. A meta-analysis
by Jaff et al.,7 including 13 randomized controlled trials of systemic
thrombolysis (n ¼ 480) vs. heparin anticoagulation alone (n ¼
464), showed no reduction in recurrent PE or death. In another
meta-analysis byWan et al., five trials were identified which included
high-risk PE patients. A significant decrease of recurrent PE or death
from 19% with heparin alone to 9.4% with thrombolysis (odds ratio:
0.45, 95%CI: 0.2220.92)wasobserved.11 In themeta-analysis by Jaff,
there was a non-significant increase in major bleeding complications
with systemic thrombolysis vs. heparin alone (10.1 vs. 7.3%, odds
ratio: 1.53, 95% CI: 0.86–2.74), and a significant increase of overall
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bleeding complications (24.1 vs. 13.8%, odds ratio: 2.16, 95% CI:
1.25–3.71).7 The risk of bleeding complications was confirmed in
the Pulmonary Embolism International Thrombolysis (PEITHO) trial
comparing a single, weight-adapted i.v. bolus of tenecteplase with
standard anticoagulation alone in 1006 patients with intermediate-risk
PE.12 This large trial showed a significant reduction in the combined
primary endpoint of all-cause mortality and haemodynamic collapse
within 7 days of randomization in favour of tenecteplase. The main
driver for the efficacy difference was not mortality but a reduction in
haemodynamic collapse in favour of tenecteplase.13 Unfortunately,
the benefits of thrombolysis came at the cost of an increased risk of
non-intracranialmajorbleedings (6.3 vs. 1.5%, P, 0.001) and intracra-
nial haemorrhage (2.4% vs. 0.2%, P, 0.001).13 In registries, systemic
thrombolysis was associated with major bleeding rates reported as
high as 20%, with intracranial haemorrhage in up to 3%.3,14
Of note, systemic thrombolysis is nowadayswithheld inmore than
two-thirds of patients with high-risk PE.15,16 The proportion of un-
stable PE patients receiving thrombolytic therapy in the USA
decreased from 40% in 1999 to 23% in 2008.17 The reasons for the
decrease in systemic thrombolysis over the last years remain
unclear and cannot be explained by increased use of catheter-based
or surgical revascularization.17
Catheter-based therapy and surgical embolectomy are alternative
revascularization strategies forpatients at increased riskofdeath, espe-
cially if the bleeding risk under systemic thrombolysis is increased.2,7,8
Catheter-based revascularization
for pulmonary embolism
The aim of catheter-based revascularization treatment is to remove
the obstructing thrombi from the main or lobar pulmonary arteries,
to facilitate right ventricular recovery, to improve symptoms, and to
reduce mortality and long-term complications.18 Contemporary
catheter-based revascularization techniques for PE can broadly be
classified as interventions with local thrombolysis and those
without thrombolysis. The latter techniques are being used for
patients with absolute contraindications to thrombolysis and com-
prise thrombus fragmentation, rheolytic or rotational thrombec-
tomy, or suction thrombectomy.7,18 Intraclot administration of
thrombolytic drugsmight bemoreefficient than systemic thromboly-
sis since the systemically administered drug is rapidly washed into
non-occluded arteries and may partly not reach obstructive throm-
bus as shown in an animal flow dynamics model by Schmitz-Rode
et al.19 The administration of local thrombolysis can be performed
with conventional catheter-directed thrombolysis (CDT) through
a multi-sidehole catheter placed into the thrombus, or with pharma-
comechanical thrombolysis, defined as the combination of CDTwith
a mechanical catheter-based technique.
Most evidence for catheter-based interventions is based on single-
centre case series.18 In a systematic review of contemporary
catheter-based revascularization techniques including 594 PE
patients in 35 studies (6 prospective and 29 retrospective), the
pooled clinical success rate, defined as stabilizationof haemodynamic
parameters, resolution of hypoxia, and survival to discharge, was
86.5%.20 Clinical success rate was higher in studies in which at least
80% of patients received local thrombolytic therapy during the
procedure. However, a direct comparison of techniques with or
without local administration of thrombolytic drugs was not possible.
Therefore, it remains debatable if catheter interventions without ad-
junctive thrombolysis are effective. Overall, minor and major peri-
procedural complications occurred in 7.9 and 2.4%, respectively,
and a total of five procedural-related deaths were reported.20
What is ultrasound-assisted
thrombolysis?
Ultrasound-assisted thrombolysis may be considered as pharmaco-
mechanical thrombolysis and consists of a combination of CDT
with a catheter system that employs ultrasound energy.21 Basic re-
search has demonstrated that ultrasound facilitates the delivery of
thrombolytic agents into blood clots.22–24 Braaten et al.23 showed
in vitro that ultrasound exposure causes a reversible disaggregation
of uncrosslinked fibrin fibres, an effect that may create additional
binding sites and facilitate the thrombolysis effect. In addition, ultra-
sound pressure waves may increase thrombus penetration of
thrombolytic drugs by acoustic streaming.22
The EkoSonicw Endovascular System (EKOS Corporation; Bothell,
WA,USA) is currently theonly commerciallyavailable catheter system
for intravascularultrasound-assisted thrombolysis. It combinesamulti-
sidehole drug infusion catheter with a multi-element ultrasound core
wire (Figure 1). The thrombolytic drug is delivered through the infusion
catheterwhile the ultrasound core delivers high-frequency (2.2 GHz),
low energy (0.5 W per transducer) intravascular ultrasound along the
entire treatment zone (Figure 2). The EkoSonic Endovascular System
Figure 1 Tip of the ultrasound-assisted thrombolysis catheter,
EkoSonicw Endovascular System (EKOS Corporation; Bothell,
WA, USA). The catheter is composed of a 5.2-Fr multi-sidehole
drug infusion catheter (treatment zone marker delineated with an
arrow head) and a microsonic core wire containing the ultrasound
elements (marked with small arrows). During ultrasound-assisted
thrombolysis, the multi-element ultrasound core wire is placed
inside the infusion catheter.
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wasclearedby theUSFDAin2008 for the infusionof solutions into the
pulmonary arteries and is C.E. certified for intravascular applications.
The superiority of ultrasound-assisted thrombolysis over conven-
tionalCDThasnotyetbeenproved inaclinical setting.Tworandomized
controlled trials are ongoing, one in patients with ilio-femoral deep vein
thrombosis (NCT01482273) and one in patients with thrombosed
infra-inguinal native arteries or bypass grafts (ISRCTN72676102). In a
non-randomized, retrospective study of 25 patients with acute PE,
ultrasound-assisted thrombolysis provided better thrombus removal,
and both thrombolytic infusion time and treatment-related complica-
tions were reduced compared with CDT alone.25
Ultrasound-assisted thrombolysis
for acute pulmonary embolism
Overall, seven studies with a total of 197 patients treated by
ultrasound-assisted CDT were published (Table 1).21,25–30
Thirty-five (18%) of the treated patients had high-risk PE. Recombin-
ant tissue plasminogen activator (rt-PA) was used as thrombolytic
drug in 195 (99%) patients with a mean total dose ranging from
17.2 to 35.1 mg. In two studies, an intrapulmonary bolus of rt-PA
was administered prior to ultrasound-assisted thrombolysis in high-
risk PE patients.21,29 Treatment duration varied largely between the
studies and was often guided by improvement in clinical or angio-
graphic parameters.25–28 Two studies used a fixed-dose treatment
regimen with 10 mg of rt-PA per treated lung over the course of
15 h.21,30
An increased right-to-left ventricular end-diastolic diameter ratio
(RV/LV ratio) assessed by echocardiography or chest CT as a sign of
right ventricular dysfunction is a validated parameter which predicts
short-termmortality for PE patients.31,32 In the three studies report-
ing the RV/LV ratio before and after ultrasound-assisted thromboly-
sis, the pooled mean RV/LV ratio decreased from 1.36 to 1.03
(Table 1).21,29,30 This reduction is similar to the treatment effect
observed in the randomized controlled Tenecteplase Italian
Pulmonary Embolism (TIPES) trial, comparing weight-adjusted i.v.
tenecteplase vs. standard therapy with unfractionated heparin
alone in patients with intermediate-risk PE. The RV/LV ratio
decreased from1.36 at baseline to 1.04 over 24 h in the tenecteplase
group,while no significant reductionof theRV/LV ratiowasobserved
in the control group (1.32–1.22).33
Compared with baseline values, mean pulmonary artery pressure
significantly decreased, and cardiac index increased at completion of
ultrasound-assisted thrombolysis in two studies.21,30 Although the
long-term benefit of early haemodynamic improvement is a matter
of debate, there is evidence to suggest that a revascularization
therapy with early improvement of haemodynamic parameters po-
tentially reduces the incidence of chronic pulmonary hypertension,
a rare but serious long-term complication.34–36
In four studies, pulmonary thrombus load was assessed pre- and
post-ultrasound-assisted CDT using various angiographic scores.
Relative reduction in the pulmonary occlusion score ranged from
32 to 69% (Figure 3).
In thepooledanalysisof availableultrasound-assistedCDTstudies,
the rate of major bleeding complications was 3.6% (95% CI: 1.4–
7.2%) (Table 1). Of note, none of the studies reported fatal or intra-
cranial bleedings. Procedure-related minor bleedings occurred in
10.7% (95% CI: 6.7–15.8%). Overall mortality rate at 3 months was
3.6% (95% CI: 1.4–7.2%). Although the overall complication rate
with ultrasound-assisted CDT for PE seems to be low, more data
are required to confirm the favourable safety profile. A single-arm,
multicentre trial (NCT01513759) designed to confirm the safety of
ultrasound-assisted CDT for patients with acute intermediate- and
high-risk PE is ongoing.
ULTIMA trial
The ULTrasound accelerated thrombolysIs of pulMonAry embolism
(ULTIMA) trial is the first randomized catheter intervention study for
patients with acute PE.30 Thismulticentre trial performed in Switzer-
land and Germany investigated whether ultrasound-assisted CDT is
Figure 2 (left panel) Baseline selective conventional pulmonary angiography showing a near complete filling defect of the right main and lower
lobe pulmonary artery (thrombusdelineatedby arrowheads). (middle panel) Baseline selective pulmonary angiography showing a partially occlusive
thrombus in the left main and lower lobe pulmonary artery, respectively (thrombus delineated by arrow heads). (right panel) Fluoroscopic anterio-
posterior view after placement of two 12-cm treatment zone EkoSonic devices with radio-opaque treatment zonemarkers (delineated with arrow
heads) and ultrasound elements (one of them marked with a small arrow).
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Table 1 Summary of published studies on ultrasound-assisted thrombolysis for acute pulmonary embolism
First author and year of
publication
No. of
patients
Patients with
high-risk PE
Total rt-PA
dose (mg)
Total
thrombolysis
duration (h)
RV/LV ratio Mean pulmonary
artery pressure
(mmHg)
Cardiac index
(l/min/m2)
Relative
reduction in
pulmonary
occlusion
score (%)
Bleeding
complications
Mortality
at 3 months
Before After Before After Before After Minor Major
Chamsuddin et al. (2008)26 10 NA 21.8 24.8+ 8.4 NA NA NA NA NA NA NA 2 (20) 0 (0)a 0 (0)
Lin et al. (2009)25 11 2 (18) 17.2+ 2.4 17.4+ 5.2 NA NA NA NA NA NA 69.0b 0 (0) 0 (0)c 1 (9)
Engelhardt et al. (2011)29 24 5 (21) 33.5+ 15.5 19.7+ 8.1 1.33+ 0.24d 1.0+ 0.13d NA NA NA NA 51.1e 2 (8) 4 (17)f 0 (0)
Quintana et al. (2013)27 10 2 (20) 18 (7–38)g 20.8 (12–49)g NA NA NA NA NA NA 41.9h 2 (20) 0 (0)i 0 (0)
Kennedy et al. (2013)28 60 12 (20) 35.1+ 11.1 19.6+ 6.0 NA NA 27+ 9 20+ 6 NA NA 32.0b 1 (2) 1 (2)a 4 (7)
Engelberger et al. (2013)21 52 14 (27) 21.0+ 5.7 15.2+ 1.7 1.42+ 0.21j 1.06+ 0.23j 37+ 9 25+ 8 2.0+ 0.7 2.7+ 0.9 NA 11 (21) 2 (4)k 2 (4)
Kucher et al. (2013)30 30 0 (0) 20.8+ 3.0 15.0+ 1.0 1.28+ 0.19j 0.99+ 0.17j 30+ 9 24+ 7 2.5+ 0.5 3.9+ 2.3 NA 3 (10) 0 (0)k 0 (0)
Totall 197 35 (18) 26.9m 17.8m 1.36+ 0.21 1.03+ 0.20 31.3+ 9.0 22.7+ 6.9 2.2+ 0.7 3.1+ 1.3 41.2 21 (10.7) 7 (3.6) 7 (3.6)
Data presented as number (%) or means+ standard deviation if not otherwise stated; NA, not available; rt-PA, recombinant tissue plasminogen activator; RV/LV-ratio, right-to-left ventricular end-diastolic diameter ratio.
aAs defined by the Society of interventional Radiology.41
bAssessed by angiographic Miller index.38
cMajor bleeding defined as intracranial bleeding or bleeding resulting in death, transfusion, surgery, or unplanned cessation of thrombolytic drug.
dAssessed by chest computed tomography.
eAssessed by modified Miller score.39
fDefined as intracranial bleeding or bleeding severe enough to warrant cessation of therapy or blood transfusion.
gMedian dose and (range).
hAssessed by Mastora score.40
iNo clear definition of major bleeding available.
jAssessed by echocardiography.
kAs defined by the International Society on Thrombosis and Haemostasis.42
lPooled means+ standard deviation derived from pooled variance analysis.
mPooled mean without study by Quintana et al.27
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superior to anticoagulation alone in the reversal of RV dilatation in
intermediate-risk PE patients. The authors hypothesized that
ultrasound-assisted CDT would have a similar effect on reducing
RV/LV ratio at 24 h when compared with i.v. tenecteplase and used
the mean and standard deviations of the difference in the RV/LV
ratio of the tenecteplase (0.31+0.20) and heparin groups (0.10+
0.30) from the TIPES trial.33 The estimated sample size was 24 per
group using a power of 80% at a two-sided P-value of 0.05 by the
t-test. Patients with acute symptomatic PE (symptom duration of
,14 days) confirmed by contrast-enhanced CT with embolus
located in at least one main or proximal lower lobe pulmonary
artery and an RV/LV ratio ≥ 1 obtained from the echocardiographic
apical four-chamber viewwere included. Patientswith known signifi-
cant bleeding riskor intolerance to the administered treatment drugs
were excluded. Ultrasound-assisted CDTwas performed according
to a standardized treatment protocol over the course of 15 h with a
rt-PA dose of 20+1 mg for patients with bilateral device placement
and10+0.5 mg forpatientswithunilateraldeviceplacement.A total
of 59patientswererandomized, 30 in the interventional groupand29
in the control group. In the interventional group, the RV/LV ratiowas
reduced from 1.28+0.19 at baseline to 0.99+ 0.17 at 24 h (P,
0.001), while in the control group no significant decrease of
the RV/LV ratio was observed at 24 h (1.20+ 0.14 vs. 1.17+ 0.20;
P ¼ 0.31). The mean difference in the RV/LV ratio from baseline to
24 h was 0.30+0.20 vs. 0.03+ 0.16 (P, 0.001), respectively.
Although there was a late ‘catch-up’ in patients with heparin alone,
there was a trend for greater improvement in the RV/LV ratio from
baseline to 90 days in favour of ultrasound-assisted CDT (0.35+
0.22 vs. 0.24+0.19; P ¼ 0.07). Right ventricular systolic function
wasgraded in fourcategoriesby thecore laboratory: normal,mild,mod-
erate, or severe dysfunction. Therewas significantly improved right ven-
tricular systolic function at 90 days in favourof ultrasound-assistedCDT
(2.2+0.9 vs. 1.5+0.9 categories; P¼ 0.01). In both study groups,
bleeding complications were rare, with three (10%) minor bleedings in
the interventional group and one (3%) in the control group. There
was no major bleeding. The authors concluded that a standardized
ultrasound-assisted thrombolysis treatment regimen for patients
with intermediate-risk PE was superior to anticoagulation alone in
reversing right ventricular dilatation at 24 h without increasing the
bleeding risk.
Practical aspects for
ultrasound-assisted thrombolysis
Patients undergoing invasive pulmonary angiography and catheter
intervention require continuous haemodynamic and electrocardio-
graphic monitoring.18 Venous access is usually obtained at the
common femoral vein using a 6 French introducer sheath for patients
who are scheduled for unilateral catheter placement or a 10 French
double-lumen introducer sheath for those who were scheduled for
bilateral catheter insertion. Duplex sonography is recommended in
patients with leg swelling to rule out concomitant ilio-femoral deep
vein thrombosis beforeobtaining venous access. In patientswith con-
comitant ilio-femoral deep vein thrombosis, the contralateral
common femoral vein may be used for venous access. A standard
5-French angiographic catheter can be used with manual injections
of a small amount of iodine contrast medium for localizing the
embolic occlusion. A 12-cm treatment zone catheter is appropriate
in most cases. To minimize the risk of pulmonary artery perforation,
only the main and lower lobe pulmonary arteries should be consid-
ered for catheter placement and segmental brancheswith a diameter
of,6 mm should not be approached.37 An intrapulmonary bolus of
thrombolytic drug (e.g. 2–5 mg rt-PA per catheter) may be injected
prior to initiating ultrasound-assisted thrombolysis in patients with
high-risk PE. In most patients with intermediate-risk PE, the initial
bolus should be omitted. Infusion of the thrombolytic drug (e.g.
rt-PA at 0.5–1.0 mg/h per catheter) and saline coolant (e.g. at
35 mL/h per catheter) over 15–24 h is initiated. Thereafter, the
patient should be continuously monitored in an intermediate or in-
tensive care unit. Treatment duration can be guided by clinical para-
meters, alternatively, a fixed-dose 15-h regimen as in the ULTIMA
trial may be used. It is suggested to measure pulmonary artery
Figure 3 (left panel) Baseline contrast-enhanced chest computed tomography of the same patient as in Figure 2 showing a saddle embolus (deli-
neatedwith arrow heads), a near complete occlusion of the right main pulmonary artery (small arrow) and a partial occlusion of the left lower lobe
pulmonary artery (large arrow). (right panel) Follow-up contrast-enhanced chest computed tomography from the same patient 24 h after termin-
ation of ultrasound-assisted catheter-directed thrombolysis showing resolution of the saddle embolus and evidence of residual non-obstructive
embolus in the right lower lobe pulmonary artery (small arrow).
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pressure pre- and post-ultrasound-assisted CDT to confirm treat-
ment success.
Limitations of ultrasound-assisted
thrombolysis for acute pulmonary
embolism
Although 18% of the treated patients were at high risk, it remains
unclear if ultrasound-assisted CDT including an intrapulmonary
bolusof thrombolytic drug acts fast enough topreventhaemodynam-
ic deterioration and death in unstable patients. In these patients, sys-
temic thrombolysis or surgical embolectomy remains the preferred
therapeutic options. Additional limitations of ultrasound-assisted
CDT include long durationof the procedure (15–24 h), limited avail-
ability in the majority of hospitals, high costs, learning curve, and no
long-term data with regard to recurrent PE, mortality, and the risk
of chronic thrombo-embolic pulmonary hypertension.
Conclusion
In PE patients at intermediate risk of death, catheter-based therapy has
emerged as alternative revascularization strategy to systemic thromb-
olysis or surgical embolectomy. Ultrasound-assisted CDT is superior
to anticoagulation alone in reversing RV dilatation in patients with
intermediate-risk PE. Available data suggest a low major bleeding rate
following ultrasound-assisted thrombolysis, but clinical outcome
studies are warranted to confirm a favourable safety profile. For un-
stable patients with high-risk PE, ultrasound-assisted thrombolysis is a
potentially promising but unproven technique. In practice, ultrasound-
assisted CDTmay be indicated in selected patients with intermediate-
or high-risk PE if the bleeding risk under systemic thrombolysis is
increased. Ideally, these procedures are performed in experienced
centres with around-the-clock availability of catheter therapy and sur-
gical embolectomy.
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Coronary artery disease in systemic sclerosis not clinically apparent: findings
from optical coherence tomography
Chiara Bernelli*, Kenichi Komukai, Vasile Sirbu, Aurelia Grosu, and Giulio Guagliumi
Interventional Cardiology Unit, Ospedale Papa Giovanni XXIII, Piazza OMS 1, Bergamo 24127, Italy
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A 42-year-old female was referred for intermit-
tent effort angina. She had low body mass index,
no coronary risk factors and an unremarkable
past medical history except for a Raynaud’s phe-
nomenon. Owing to a normal exercise stress
test (Panel A), symptoms were initially attributed
to anxiety. However, a 24h-EKG monitoring
revealed diffuse ST-segment depression during
physical activity (Panel B). On admission, CT scan
showed low-density areas at proximal/mid seg-
ments of the left anterior descending artery
(LAD), without calcifications (Panel C). At coron-
ary angiography LAD presented with a long, sub-
occlusive stenosis (Panels D and E) with collaterals from the right coronary artery. Optical coherence tomography (OCT)
demonstrated diffuse intimal-medial thickening of the LAD, a finding suggestive for a fibrotic process involving the vessel (Panel F and Sup-
plementary material online, Video S1). Intravascular ultrasound showed constrictive vessel remodeling (Panel G). Two everolimus-eluting
stentswere implanted inoverlap in theLADwithoptimal final result (Supplementarymaterial online, Figures S1and S2).AnOCTpullbackof
the radial artery documented focal intimal thickening, suggesting different stages of vascular involvement of the medium-small arteries
(Panel H). A videocapillaroscopy (Panel I) identified typical features of early scleroderma peripheral microangiopathy, with giant capillaries
and haemorrhages. Systemic sclerosis (SSc)-related autoantibodies were still negative.
Systemic sclerosis has a strong macrovascular component with an increased risk of heart attack. Involvement of the medium-small ar-
teries is one of the earliest features of SSc preceding the widespread fibrosis. The present case demonstrates howOCTmay orient in the
diagnosis and treatment of an uncommon cause of CAD such as SSc not clinically apparent yet.
Supplementary material is available at European Heart Journal online.
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